Orsini Now Dispensing Livdelzi for Rare Liver Disease

Orsini has been chosen by Gilead Sciences, Inc. to dispense Livdelzi® (seladelpar), an oral medication approved by the U.S. Food and Drug Administration (FDA) on August 14, 2024, for the treatment of Primary Biliary Cholangitis (PBC).

PBC is a rare, chronic liver disease where bile flow is compromised, causing bile acids to accumulate in the liver and elevate liver enzyme levels to potentially dangerous heights. This condition primarily affects about one in 1,000 women over the age of 40 and is accompanied by symptoms such as fatigue, itching, poor appetite, weight loss, and an elevated risk of liver-related mortality.

Orsini will now be dispensing Livdelzi® (seladelpar), which offers a vital treatment route for managing and slowing the progression of Primary Biliary Cholangitis. "Livdelzi is an important treatment option to slow the progression of PBC and transform patients' quality of life," remarked Brandon Tom, CEO of Orsini. "We're thrilled to partner with Gilead to address this need for people living with PBC and their families."

Orsini has been providing comprehensive and compassionate patient care since 1987 and stands as a leader in managing rare diseases and gene therapies. The company collaborates with biopharma innovators, healthcare providers, and payors to help patients and their families gain access to groundbreaking treatments for rare diseases. Orsini offers integrated rare disease pharmacy solutions that include pharmacy distribution, patient services, clinical management, and home infusion services, simplifying the process for patients to receive advanced therapies. Their high-touch care model revolves around experienced and trained therapy care teams that deliver personalized patient care to ensure that no patient is left behind.

Orsini Specialty Pharmacy holds several accreditations: from the Accreditation Commission for Health Care (ACHC), The Joint Commission, URAC, and NABP. Moreover, Orsini has received URAC's Rare Disease Pharmacy Center of Excellence Designation and ACHC's Distinction in Rare Diseases and Orphan Drugs.